At concentrations <5 μM IQcs 2d, 3d and 3e inhibited KRAS promoter activity by up to 50% in the luciferase dual-reporter assay (Figure 5) and inhibited mutated KRAS expression at both mRNA and protein levels in the HCT116 and metastatic SW620 colon cancer cell lines (Figure 6). Here, KRAS is linked to colonic neoplasm.